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f Rhythm Management (AFFIRM) Study
Multivariate Analysis
lizabeth S. Kaufman, MD, FACC,* Paul A. Zimmermann, MD, FACC,† Ted Wang, MD, FACC,‡
eorge W. Dennish III, MD, FACC,§ Patrick D. Barrell, BS, Mary L. Chandler, MD, FACOG,
. Leon Greene, MD, FACC, and the AFFIRM Investigators
leveland, Ohio; Columbia, South Carolina; Chicago, Illinois; La Jolla, California; and Seattle, Washington
OBJECTIVES This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic
drugs for treatment of atrial fibrillation (AF) according to present-day safety guidelines.
BACKGROUND Advances in understanding the proarrhythmic risk of antiarrhythmic drugs has led to
development of safety guidelines for these agents. Such guidelines were used in the Atrial
Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
METHODS This study was an analysis of the risk of arrhythmic events (arrhythmic death, resuscitated
cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) in the
antiarrhythmic drug arm of the AFFIRM study. Each time an antiarrhythmic drug was
begun, it was counted as an exposure to that drug and the risk of an arrhythmic event was
calculated.
RESULTS A total of 2,033 patients received 3,030 exposures to antiarrhythmic drugs. Ninety-six
arrhythmic events occurred by six years. Patients with a left ventricular ejection fraction40%
had more arrhythmic events. Twelve documented cases of torsade de pointes VT were noted.
The incidence of torsade de pointes was 0.6% at five years (95% confidence interval 0.32 to
1.07).
CONCLUSIONS The overall risk of adverse arrhythmic events upon exposure to antiarrhythmic drugs in the
AFFIRM study was reasonably low. Strict criteria for the safe use of antiarrhythmic drugs
were successful in minimizing proarrhythmic events. (J Am Coll Cardiol 2004;44:
1276–82) © 2004 by the American College of Cardiology Foundationt
o
a
a
w
t
p
f
v
t
a
M
P
A
(
t
u
r
w
s
u
o
pntiarrhythmic drugs can cause a substantial risk of pro-
rrhythmia, a potentially lethal drug-induced provocation or
orsening of cardiac arrhythmias (1–3). Previous studies,
specially in the past two decades, have led to heightened
wareness of this risk and to guidelines for safer use of
ntiarrhythmic agents (4–6). The present-day risk of
roarrhythmia, when safety guidelines are followed, is not
nown. Because atrial fibrillation (AF) is treated with a
ariety of antiarrhythmic drugs, we evaluated the risk of
roarrhythmia and arrhythmic death in patients treated
ith drugs administered to maintain sinus rhythm in the
trial Fibrillation Follow-up Investigation of Rhythm
anagement (AFFIRM) study, a clinical trial that
mposed formal restrictions on the use of these drugs (7–9).
Certain populations are at increased risk of proarrhythmia
rom specific antiarrhythmic agents. Women are more
usceptible than men to torsade de pointes ventricular
From the *MetroHealth Campus of Case Western Reserve University, Cleveland,
hio; †South Carolina Heart Center, Columbia, South Carolina; ‡Advocate Illinois
asonic Medical Center, Chicago, Illinois; §Scripps Memorial Hospital, La Jolla,
alifornia; and Axio Research Corporation, Seattle, Washington. Supported under
ontract N01-HC-55139 by the National Heart, Lung, and Blood Institute. The
FFIRM investigators and their affiliations are listed in reference 8.
Manuscript received March 22, 2004; revised manuscript received June 5, 2004,tccepted June 14, 2004.achycardia (VT) (10–14), a morphologically distinct form
f VT distinguished by its polymorphic appearance and
ssociation with a prolonged QT interval, caused by anti-
rrhythmic drugs (Vaughan Williams class IA and III),
hich prolong cardiac repolarization (15,16). Serious struc-
ural heart disease confers an increased risk of ventricular
roarrhythmia (and, in particular, proarrhythmic death)
rom antiarrhythmic medication (5,17,18). We used multi-
ariate analysis to determine the effects of clinical charac-
eristics on the risk of proarrhythmia in the rhythm-control
rm of the AFFIRM study.
ETHODS
atients. The methods and enrollment criteria for the
FFIRM study have been described in detail elsewhere
7–9). Briefly, eligible patients had AF requiring long-term
reatment either with drugs intended to control the ventric-
lar response during AF (rate-control group) or antiar-
hythmic drugs (rhythm-control group). Eligible patients
ere either 65 years of age or had another risk factor for
troke or death and had no contraindication to anticoag-
lation. The institutional review boards of the University
f Washington and of all enrolling sites approved the
rotocol. Each patient gave written informed consent for
he study.
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September 15, 2004:1276–82 Proarrhythmic Events in the AFFIRM Studyntiarrhythmic drug therapy. Once assigned to the
hythm-control group, patients received antiarrhythmic drug
reatment as chosen by their physicians. Possible therapy
ncluded quinidine, procainamide, disopyramide, flecainide,
ropafenone, moricizine, sotalol, and amiodarone. Dofetilide
able 1. Antiarrhythmic Drug Use (7–9)
Drug Starting Dose
Minimum
Maintenance
Dose (mg/day)
lass I
Quinidine 600
Procainamide 1,500
Disopyramide 300
Moricizine 400
lass I-C
Propafenone 450
Flecainide 100
lass III
Dofetilide Not specified
Ibutilide Not applicable
Sotalol 160 mg/day 240
Amiodarone 10 g over 1 or
more weeks
200
100 mg/day could be used if adverse effects required a lower dose, and higher dos
areful monitoring for proarrhythmia, bradycardia, and hypokalemia; caution for the n
aution in patients with LVH or organic heart disease; atrioventricular nodal blocking
Any drug associated with prior inefficacy, intolerable adverse effects, or torsades cou
CAD  coronary artery disease; CHF  congestive heart failure; ECG  electro
entricular hypertrophy; Stress test  evaluation for stress-induced ischemia (exercise
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management
CI  confidence interval
LV  left ventricular
VT  ventricular tachycardiacan, or pharmacologic stress echocardiogram), alternatively, a normal coronary angiogramecame available during the latter part of the study and was also
n acceptable treatment. The protocol specified guidelines for
he use of specific antiarrhythmic drugs in accordance with
tandard safe practice (e.g., flecainide was not to be prescribed
or patients with coronary artery disease or left ventricular [LV]
ysfunction) (Table 1). Drug doses were adjusted based on
enal and hepatic function, and patients were monitored for
lectrocardiographic changes (7). Patients whose therapy with
he initial drug choice failed could have a different drug
dministered.
Exposure to the various antiarrhythmic drugs was tabu-
ated at each follow-up visit. Any administration of an
ntiarrhythmic drug was considered to be an exposure to
hat drug. The precise duration of time that a person was
Precautions† Contraindications‡
Left ventricular dysfunction
CHF
Low LVEF
Ischemic heart disease
Blood counts weekly for 12 weeks
and as needed thereafter
Blood tests for lupus syndrome every
3–6 months
LVEF 0.30
Required for use of class I-C agents: CHF
Normal LV Structural heart disease
Normal stress test Myocardial disease
LVH
CAD
Abnormal LV function/
wall motion
LVEF 0.50
In-hospital administration for a
minimum of 3 days
Measurement of renal function
ECG monitoring
In-hospital administration
ECG monitoring
Asthma
Renal dysfunction
requiring dialysis
Current CHF class  II
History of CHF and
LVEF  0.30 or
LVEF  0.25
to 400 mg/day) could be used, as necessary. †General precautions to be observed:
inotropic effects of drugs; QTc must not exceed 0.52 s after drug titration; particular
o be given as appropriate; monitoring for renal and hepatic dysfunction in the elderly.
t be used again.
gram; LV  left ventricular; LVEF  left ventricular ejection fraction; LVH  left
tress thallium or sestamibi, stress echocardiogram, pharmacologic stress radionuclidees (up
egative
drugs t
ld no
cardio
test, scould substitute for the stress test.
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Proarrhythmic Events in the AFFIRM Study September 15, 2004:1276–82xposed to a drug was not reported. Drug levels were not
eported, though they may have been performed locally and
sed to monitor drug dosing. Doses likewise were not
eported to the AFFIRM study coordinating center.
Drugs considered to pose the most serious risk for QT
rolongation and proarrhythmia were quinidine, procain-
mide, disopyramide, sotalol, ibutilide, and dofetilide. Ami-
darone was thought to have a lesser risk of QT prolonga-
ion and proarrhythmia.
ata acquisition. Data collected prospectively included
aseline clinical characteristics, drugs taken, electrocardio-
raphic parameters, and the reporting of significant arrhyth-
ic events: resuscitated cardiac arrest, torsade de pointes
T, sustained VT, and arrhythmic death. These arrhythmic
vents were adjudicated by an Events Committee blind to
reatment arm and drug assignment (19). This substudy was
esigned after initiation of the AFFIRM study protocol, but
efore results were available. Analysis was performed by
ntention-to-treat.
tatistical analysis. Student t test was used to compare
ontinuous variables. Chi-square analyses were used to
ompare categorical values; when one or more expected cell
requencies were 5, Fisher exact tests were used instead of
he chi-square approximation. Kaplan-Meier methods were
sed to determine event-free survival, and groups were
ompared using log-rank tests. A Cox proportional hazards
odel was used to adjust for significant covariates. Some
nalyses were restricted to subjects who were exposed to
rugs more likely to prolong the QT interval (quinidine,
rocainamide, disopyramide, sotalol, ibutilide, and
ofetilide).
ESULTS
haracteristics of study population. Of 4,060 patients
Table 2. Baseline Characteristics
Total
n 2,033
Age 69.7  9
History of CAD 794 (3
History of MI 373 (1
History of CHF 464 (2
History of hypertension 1,442 (7
History of valvular heart disease 240 (1
History of diabetes 389 (1
History of hepatic or renal disease 102 (5
History of smoking 255 (1
Rhythm at randomization
Atrial fibrillation or flutter 894 (4
Sinus rhythm 1,040 (5
Left ventricular ejection fraction
Normal (50%) 1,113 (7
Mild dysfunction (40%–49%) 200 (1
Moderate dysfunction (30%–39%) 134 (9
Severe dysfunction (30%) 74 (5
Data are presented as n (%) or mean  SD.
CAD  coronary artery disease; CHF  congestive hearnrolled in the AFFIRM study, 2,033 were randomized to che rhythm-control arm of the study to receive antiarrhyth-
ic drugs for treatment of AF and form the basis for this
nalysis (8,9). Patients were followed for an average of 3.5
ears.
Table 2 displays the baseline patient characteristics,
ighlighting a comparison between women and men.
omen were older (p  0.0001) and more had valvular
eart disease (p  0.0001). Men were more likely to have
oronary artery disease (p  0.0001), past myocardial
nfarction (p  0.0001), hepatic or renal disease (p 
.025), history of smoking (p  0.0004), AF at the time of
andomization (p  0.03), and abnormal LV function (p 
.0001). The ejection fraction was not available in 25% of
omen and 25% of men.
rugs used. Initial antiarrhythmic drug therapy and over-
ll exposure to antiarrhythmic agents are shown in Table 3.
ore men were prescribed amiodarone, and more women
sed disopyramide, flecainide, and propafenone. In follow-
p, more women used diuretics.
rrhythmic events. The cumulative incidence of all ar-
hythmic events at six years was 7%, 6% in women (34
vents in 771 patients), compared with 7% in men (62
vents in 1,262 patients). Figure 1 shows that the Kaplan-
eier estimates of the cumulative incidence of a first
entricular proarrhythmic event by five years among the
,047 patients exposed to drugs known to have a high risk
f QT prolongation (quinidine, procainamide, disopyr-
mide, sotalol, ibutilide, and dofetilide) was 5% in women
n 14 events) and 5% in men (n 23 events). Congestive
eart failure increased the risk of proarrhythmia to 9.7% at
ve years, compared to 4.0% in those without congestive
eart failure (p  0.001). After adjusting for gender, the
redictors of ventricular proarrhythmic events in all patients
ere age 65 (hazard ratio  1.96, p  0.03), history of
Women Men p Value
771 1,262
71.8  8.6 68.4  9.0 0.0001
236 (31) 558 (44) 0.0001
102 (13) 271 (21) 0.0001
177 (23) 287 (23) 0.91
562 (73) 880 (70) 0.13
122 (16) 118 (9) 0.0001
139 (18) 250 (20) 0.32
28 (4) 74 (6) 0.025
71 (9) 184 (15) 0.0004
315 (43) 579 (48) 0.03
416 (57) 624 (52)
475 (82) 638 (68) 0.0001
55 (10) 145 (15)
32 (6) 102 (11)
17 (3) 57 (6)
re; MI  myocardial infarction..0
9)
8)
3)
1)
2)
9)
)
3)
6)
4)
3)
3)
)
)ongestive heart failure (hazard ratio  2.68, p  0.0001),
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September 15, 2004:1276–82 Proarrhythmic Events in the AFFIRM Studynd mitral regurgitation2/4 (hazard ratio 2.04, p
.003). After adjustment for significant covariates, gender
id not confer any additional risk for ventricular proarrhyth-
ic events.
The incidence of torsade de pointes VT was low and
imilar in women and men, 7 versus 5 (1.0% and 0.4%)
Tables 4 to 6). The QTc was dramatically prolonged in
ost patients with torsade de pointes at the time of the
vent, and QTc was frequently accompanied by bradycardia,
ypokalemia, or hypomagnesemia (Table 5).
ortality. Overall mortality in the rhythm control arm was
2% in women and 25% in men at five years (p  0.3024).
ISCUSSION
ow number of arrhythmic events related to selection of
ntiarrhythmic agents. In this substudy of a large group of
atients with AF treated with antiarrhythmic agents using
trict guidelines, the risk of proarrhythmia was low. The
umulative incidence of all arrhythmic events in patients
xposed to QT-prolonging drugs was 5% at five years. With
he overall mortality in the rhythm control group at 27%,
rrhythmic events were a small portion of the adverse
utcomes. Furthermore, the incidence of strokes and non-
ardiac events was much higher than the incidence of
rrhythmic events.
Torsade de pointes VT is the major type of proarrhyth-
Table 3. Drug Therapy
To
Initial antiarrhythmic drug therapy after
randomization
Quinidine 92
Disopyramide 42
Procainamide 103
Moricizine 14
Flecainide 88
Propafenone 183
Dofetilide 0
Ibutilide 0
Sotalol 612
Amiodarone 735
Antiarrhythmic drugs taken at any time
after randomization
Quinidine 139
Disopyramide 83
Procainamide 159
Moricizine 35
Flecainide 166
Propafenone 283
Dofetilide* 12
Ibutilide* 4
Sotalol 817
Amiodarone 1,257
Other drugs taken at any time after
randomization
Digoxin 1,052
Diuretic 1,332
*Fisher exact test used due to expected cell frequencies 5.ia that can be definitively ascribed to an antiarrhythmic brug. Other types of proarrhythmia (arrhythmic death,
ustained VT, resuscitated cardiac arrest) could be secondary
o the progression of intrinsic disease. Overall incidence of
orsade de pointes VT was 1% for women and 0.4% for
en. This incidence of torsade de pointes VT in the
FFIRM study was far below the rate of 2% to 10%
uggested in older literature (20–27). More recently, Hohn-
oser et al. (28) reported torsade de pointes in 13/947 (1.4%,
5% confidence interval [CI] 0.77 to 2.4) patients treated
ith sotalol, compared with 77/3,944 (2.0%, 95% CI 1.6 to
.5) patients reported by Lehmann et al (29) and 4/839
0.48%, 95% CI 0.15 to 1.3) patients given sotalol in the
FFIRM study. For dofetilide (30), torsade de pointes was
ocumented in 11/1,346 (0.82%, 95% CI 0.43 to 1.5)
atients and 4/249 (1.6%, 95% CI 0.52 to 4.3) patients in
F, compared with 1/12 (8.3%, 95% CI 0.44 to 40.3) in the
FFIRM study. The overall risk of torsade de pointes in the
FFIRM study for all subjects was 12 of 2,006 (0.6%, 95%
I 0.32 to 1.07); limiting the analysis to sotalol or dofeti-
ide, torsade de pointes was seen in 5 of 851 (0.6%, 95% CI
.22 to 1.45). This overall risk of torsade de pointes in the
FFIRM study reflects the restrictions on drug use imposed
n the AFFIRM study, as well as the drug dose adjustments
ased on drug metabolism, renal and hepatic function, and
he monitoring of electrocardiographic changes (7).
The overall number of proarrhythmic events may have
Women
(n  771)
Men
(n  1,262) p Value
32 (5) 60 (5) 0.53
28 (4) 14 (1) 0.0001
29 (4) 74 (6) 0.04
7 (1) 7 (1) 0.35
48 (7) 40 (3) 0.001
94 (13) 89 (8)  0.0001
0 0
0 0
228 (32) 384 (33) 0.69
240 (34) 495 (42) 0.0002
41 (5) 98 (8) 0.04
55 (7) 28 (2)  0.0001
52 (7) 107 (9) 0.17
14 (2) 21 (2) 0.79
87 (12) 79 (6)  0.0001
140 (19) 143 (12)  0.0001
3 (0.40) 9 (0.73) 0.55
2 (0.26) 2 (0.16) 0.64
313 (41) 504 (41) 0.71
444 (59) 813 (66) 0.003
409 (54) 643 (52) 0.31
553 (73) 779 (63)  0.0001
re presented as n (%).tal
(5)
(2)
(5)
(1)
(5)
(10)
(33)
(39)
(7)
(4)
(8)
(2)
(8)
(14)
(0.60)
(0.20)
(41)
(63)
(53)
(67)een small because of the mix of antiarrhythmic agents
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Proarrhythmic Events in the AFFIRM Study September 15, 2004:1276–82sed. Only one-third of patients took class I agents, and
oughly one-third took sotalol. One-third took amiodarone,
hich is thought to cause ventricular proarrhythmia only
arely. Class I agents have been shown to have significant
roarrhythmic effects with an associated mortality up to 6%
20–27). The risk of proarrhythmia from class I agents is
igher in patients with underlying significant structural
eart disease such as congestive heart failure (18). The
elatively low use of class I agents in this study (and the
FFIRM study guidelines designating which patient
roups could appropriately receive which specific drugs)
robably contributed to the low number of proarrhythmic
vents. Specifically, class IC drugs were prohibited in
atients with organic heart disease, and investigators were to
se caution in the use of any class I agents in patients with
V dysfunction (7).
igure 1. Time to significant ventricular arrhythmias (defined as resuscitate
achycardia, or arrhythmic death) in the antiarrhythmic drug arm of the
butilide, or dofetilide at any time.
Table 4. Arrhythmic Events
Total
(n  2,033)
Total subjects with event 96 (5)
Cardiac arrest* 16 (0.79)
Torsades de pointes VT* 12 (0.59)
Sustained VT* 5 (0.25)
Arrhythmic death 77 (4)
*Fisher exact test used due to expected cell frequencies 5.
VT  ventricular tachycardia.ffect of gender. There was no statistically significant
ender difference in the risk of arrhythmic events, including
orsade de pointes VT. However, prior studies observed an
ncreased risk for women when QT-prolonging drugs were
iven, even after correction for baseline clinical inequalities
etween men and women (12–14,31,32). There are several
lausible explanations for our results. First, the low number
f adverse events may have precluded finding a statistically
ignificant gender difference (i.e., a possible type II statisti-
al error). Second, the selection of antiarrhythmic drugs may
ave influenced the outcome. The use of antiarrhythmic
rugs was neither randomized nor blinded, and women
eceived a different mix of drugs throughout the study.
omen may have had their drug administration followed
ore closely and drugs discontinued more quickly if adverse
ffects or electrocardiographic changes appeared, in recog-
iac arrest, torsades de pointes ventricular tachycardia, sustained ventricular
IRM study exposed to quinidine, disopyramide, procainamide, sotalol,
Women
(n  771)
Men
(n  1,262) p Value
34 (4) 62 (5) 0.60
4 (0.52) 12 (1) 0.44
7 (1) 5 (0.4) 0.23
0 (0) 5 (0.4) 0.16
27 (4) 50 (4) 0.60
re presented as n (%).d card
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September 15, 2004:1276–82 Proarrhythmic Events in the AFFIRM Studyition of the literature demonstrating that women have a
igher risk for proarrhythmia (12,13,31,32). Last, the se-
erity of heart disease in this study was higher in men than
n women.
everity of underlying heart disease. It is well-established
hat LV dysfunction in a population of patients with
nderlying ischemic heart disease predisposes to arrhythmic
vents and death (33). Thus, a tendency toward more
roarrhythmia in women may have been offset by the more
able 5. Torsade de Pointes Ventricular Tachycardia
Patient
#
Age; Gender;
Diagnosis LVEF
Antiarrhythmic
Drug
Time on
Drug
1 76; F; CAD,
RHD, CHF
40%–49% amiodarone 9 days
2 78; M; CAD,
DM, COPD,
HTN, CHF,
CRF
50% quinidine 1.5 yrs
3 81; F; HTN 50% amiodarone,
ibutilide
17 min
4 68; F; HTN,
DM
50% disopyramide 4 days
5 74; M; HTN 50% amiodarone,
dofetilide
2 days
6 75; M; CAD,
HTN, CRF
50% sotalol 2.5 yrs
7 79; F; CAD,
CHF, sepsis
40%–49% amiodarone 2 months
8 69; M; HTN,
CAD
50% sotalol 2 days
9 55; M; HTN 50% amiodarone 1 yr
10 76; F; CHF,
CVA, old
MI, CAD,
DM, HTN,
new MI
NA sotalol 1 yr
11 75; F; HTN,
CAD, CHF
55% sotalol 1 month
12 52; F; DM,
HTN, new
MI, sepsis
50% amiodarone 11 months
mio  amiodarone; CAD  coronary artery disease; CHF  congestive heart failu
cerebrovascular accident; DM diabetes mellitus; ECG electrocardiogram; HTN
VEF  left ventricular ejection fraction; MI  myocardial infarction; NA  not
easurements immediately before and after torsade event. All QTc measurements a
able 6. Torsade de Pointes VT
Drug
N Exposed
to Drug
N With
Torsades % Incidence
uinidine 151 1 0.7
rocainamide 170 0 0
isopyramide 86 1 1.2
oricizine 35 0 0
lecainide 168 0 0
ropafenone 292 0 0
ofetilide 12 1 8.3
butilide 4 1 25
otalol 839 4 0.5
miodarone 1,273 5 0.4
One patient was taking both amiodarone and dofetilide at time of the event.
pVT  ventricular tachycardia.erious underlying heart disease in the men in this study.
nly age 65 years, mitral regurgitation, and congestive
eart failure were significant covariates in the multivariate
nalysis.
ime course of proarrhythmia. Importantly, torsade de
ointes VT did not necessarily occur early upon exposure to
QT-prolonging drug. Six of the 12 patients had been
eceiving their medication for more than two months and
hree were taking amiodarone alone. Other authors have
lso reported late onset of proarrhythmia (4), and the
oncept that adverse effects of antiarrhythmic drugs always
ccur early is incorrect. The fact that many of the patients
ad coexistent bradycardia, hypokalemia, and/or hypomag-
esemia emphasizes the need to avoid these conditions in
atients treated with QT-prolonging agents.
trengths and uniqueness of the study. The careful se-
ection of antiarrhythmic drugs and monitoring of their use
n the AFFIRM study was associated with a low risk of
roarrhythmic events, despite a high-risk patient popula-
ion. In contrast to many study designs, in AFFIRM study
hysicians were not blinded to patient treatment, nor
andated to administer specific drugs or doses to all
Time From ECG
o Torsade Event;
eart Rate; QTc
*Time From Torsade
Event to ECG;
Heart Rate; QTc Other
1 min; 53; 590 NA K  3.2, LBBB
NA/paced NA/paced K  3.4, Mg  1.5
3.75 h; 74; 418 5 min; 74; 600 K  4.0, Mg  1.6
On amio before ibutilide
4 days; 50; 429 20 min; 43; 576 “low K,” “low Mg”
9 h; 52; 521 13 days; 63; 422 On amio before dofetilide
2 days; 61; 535 9 h; 54; 605 K  4.8, Mg  1.4
NA NA K  3.7, pH  7.28
1 min; 48; 718 1 min; 52; 669 On amio before sotalol;
RBBB, LAFB
3 days; 56; 560 1 min; 55; 632 K  3.4, Mg “low”
NA NA K  3.3, Mg  1.7
1 month; 56; 494 1 h; 50; 548 LBBB
2 h; 98; 588 1.5 h; 91; 603 K  3.3, Mg  1.6
PD  chronic obstructive pulmonary disease; CRF  chronic renal failure; CVA
pertension; LAFB left anterior fascicular block; LBBB left bundle branch block;
ble; RBBB  right bundle branch block; RHD  rheumatic heart disease; *ECG
illiseconds.*
t
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linical practice and illustrates that thoughtful, informed
hysicians following standard safety guidelines can use
ntiarrhythmic drugs with relatively low risk.
tudy limitations. The present study was conducted in
atients with AF who were age 65 years or had another
isk factor for stroke or death. It does not necessarily apply
o other patients with AF.
This substudy was analyzed by retrospective analysis of
ata. The arrhythmia event rates were too low to detect even
ajor differences in proarrhythmic risk. Furthermore,
roarrhythmic events may have been missed or misclassi-
ed. Doses of the various antiarrhythmic drugs were not
outinely reported, nor were routine electrocardiographic
easurements, so we are unable to demonstrate any effect of
areful dose adjustments that might have occurred. The
recise duration of time that a person was exposed to a drug
as not reported, and drug levels were not measured.
onclusions. If patients with AF are treated with antiar-
hythmic agents selected appropriately and monitored care-
ully, overall proarrhythmia risk is relatively low. Drug
election is crucial, and dose adjustments are necessary,
ased on hepatic and renal function, along with monitoring
f electrocardiographic changes. These measures will help
o reduce adverse arrhythmia outcomes for patients needing
hese drugs.
eprint requests and correspondence: Dr. Elizabeth S. Kauf-
an, Heart and Vascular Research Center, Hamann 3rd Floor,
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